Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 12:53 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1177–1200 of 5,557 matching trials from the live ClinicalTrials.gov search.

Filters: Sacramento, California Clear all

Conditions: Periorbital Wrinkles, Periorbital Area, Under-eyes Dark Circles, Crows Feet
Interventions: Treatment with BTL-785 with the applicator BTL-785-7-11; Device
Lead sponsor: BTL Industries Ltd.; Industry
Eligibility: 21 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 3
States / cities: Sacramento, California • Solana Beach, California • Youngstown, Ohio

Conditions: Iron Deficiency Anemia Treatment, Chronic Kidney Disease(CKD)
Interventions: Ferumoxytol, Iron Sucrose; Drug
Lead sponsor: AMAG Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 296 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 38
States / cities: Pine Bluff, Arkansas • Azusa, California • Beverly Hills, California + 32 more

Conditions: Smoking
Interventions: TA-NIC, Placebo; Biological
Lead sponsor: Celtic Pharma Development Services; Industry
Eligibility: 18 Years and older
Enrollment: 522 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2009
U.S. locations: 9
States / cities: Sacramento, California • Metairie, Louisiana • Columbia, Maryland + 6 more

Conditions: Hemophilia A
Interventions: BIIB031 (rFVIIIFc), FVIII (PK subgroup only); Drug
Lead sponsor: Bioverativ Therapeutics Inc.; Industry
Eligibility: Up to 11 Years · Male only
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 12
States / cities: Los Angeles, California • Sacramento, California • San Diego, California + 9 more

Conditions: Cystic Fibrosis
Interventions: MP-376 (Levofloxacin Solution for Inhalation), TIS (Tobramycin Inhalation Solution); Drug
Lead sponsor: Amgen; Industry
Eligibility: 12 Years and older
Enrollment: 282 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 99
States / cities: Mobile, Alabama • Anchorage, Alaska • Phoenix, Arizona + 86 more

Conditions: Chronic Rhinitis
Interventions: RhinAer Stylus, Sham; Device
Lead sponsor: Aerin Medical; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 116 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2024
U.S. locations: 13
States / cities: Roseville, California • Torrance, California • Plantation, Florida + 10 more

Conditions: Growth Hormone Deficiency (GHD)
Interventions: LUM-201, Matched Placebo (Capsules); Drug · Other
Lead sponsor: Lumos Pharma; Industry
Eligibility: 3 Years to 11 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 31
States / cities: Birmingham, Alabama • Madera, California • Orange, California + 28 more

Conditions: Ganglioneuroblastoma, Ganglioneuroblastoma, Nodular, Neuroblastoma
Interventions: Autologous Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Busulfan, Carboplatin, Cisplatin, Computed Tomography, Cyclophosphamide, Dexrazoxane Hydrochloride, Dinutuximab, Doxorubicin Hydrochloride, Echocardiography Test, Etoposide Phosphate, External Beam Radiation Therapy, Iobenguane I-123, Iobenguane I-131, Isotretinoin, Lorlatinib, Magnetic Resonance Imaging, Melphalan Hydrochloride, Multigated Acquisition Scan, Positron Emission Tomography, Sargramostim, Therapeutic Conventional Surgery, Thiotepa, Topotecan Hydrochloride, Vincristine Sulfate; Procedure · Drug · Biological + 1 more
Lead sponsor: Children's Oncology Group; Network
Eligibility: 365 Days to 30 Years
Enrollment: 750 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2030
U.S. locations: 152
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 121 more

Conditions: Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm, Acute Myeloid Leukemia Post Cytotoxic Therapy, Acute Myeloid Leukemia, Myelodysplasia-Related
Interventions: Azacitidine, Biospecimen Collection, Bone Marrow Aspiration, Cytarabine, Daunorubicin Hydrochloride, Echocardiography Test, Liposome-encapsulated Daunorubicin-Cytarabine, Multigated Acquisition Scan, Venetoclax; Drug · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 59 Years
Enrollment: 335 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 216
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 175 more

Conditions: Behavioral Symptoms, Autistic Disorder
Interventions: Aripiprazole, Placebo; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 218 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 31
States / cities: Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 28 more

Conditions: Diabetes
Interventions: Medtronic MiniMed 530G Insulin Pump; Device
Lead sponsor: Medtronic MiniMed, Inc.; Industry
Eligibility: 16 Years and older
Enrollment: 372 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 43
States / cities: Little Rock, Arkansas • Escondido, California • Fresno, California + 38 more

Conditions: Esophageal Cancer, Gastric Cancer
Interventions: gemcitabine hydrochloride, irinotecan hydrochloride; Drug
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2006
U.S. locations: 96
States / cities: Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 61 more

Conditions: COVID-19
Interventions: PF-07304814, Placebo, Remdesivir; Drug · Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 31
States / cities: Chula Vista, California • Los Angeles, California • Mather, California + 23 more

Conditions: Idiopathic Pulmonary Fibrosis
Interventions: Simtuzumab, Simtuzumab placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 45 Years to 85 Years
Enrollment: 544 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 72
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 55 more

Conditions: Sepsis
Interventions: Intravenous GR270773- Phospholipid Emulsion, Placebo; Drug · Other
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 1,415 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 132
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 110 more

Conditions: Cervical Cancer
Interventions: carboplatin, cisplatin, paclitaxel, intensity-modulated radiation therapy, standard external beam radiation therapy, Optional brachytherapy boost; Drug · Radiation
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: 18 Years and older · Female only
Enrollment: 236 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2025
U.S. locations: 119
States / cities: Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 98 more

Conditions: Pancreatic Cancer, Pancreas Cancer, Pancreatic Diseases
Interventions: Cefoxitin, Piperacillin-tazobactam; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 967 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 29
States / cities: Sacramento, California • Atlanta, Georgia • Chicago, Illinois + 24 more

Conditions: HIV Infections, Peripheral Neuropathy
Interventions: pregabalin, Placebo; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 302 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 41
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 29 more

Conditions: Hypoxic Ischemic Encephalopathy
Interventions: Device (servo-regulated cooling), Control (standard practice); Device · Other
Lead sponsor: Stanford University; Other
Eligibility: Up to 6 Hours
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 9
States / cities: Loma Linda, California • Madera, California • Oakland, California + 5 more

Conditions: Renal Failure, End Stage Renal Disease, Hemodialysis, Vascular Access
Interventions: Human Acellular Vessel (HAV), ePTFE graft; Biological · Device
Lead sponsor: Humacyte, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 355 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 22
States / cities: Phoenix, Arizona • Tucson, Arizona • Fresno, California + 18 more

Conditions: Noninfectious Uveitis
Interventions: LX211; Drug
Lead sponsor: Lux Biosciences, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 155 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 28
States / cities: Peoria, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 24 more

Conditions: Clostridioides Difficile Infection
Interventions: SER-109; Biological
Lead sponsor: Seres Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 263 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 97
States / cities: Dothan, Alabama • Sun City West, Arizona • Mather, California + 84 more

Conditions: Depression - Major Depressive Disorder
Interventions: intermittent theta burst stimulation, Sham (No Treatment); Device
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years to 65 Years
Enrollment: 264 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Healthy Participants
Interventions: REGN10933 + REGN10987, Placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 1 Day and older
Enrollment: 3,303 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 132
States / cities: Mesa, Arizona • Tucson, Arizona • La Mesa, California + 94 more

Search by objective public record fields.

Non-invasive Rejuvenation of the Periorbital Area and Lower Eyelid

Compare Efficacy/Safety of Repeat Doses of Ferumoxytol With Iron Sucrose in CKD Subjects With IDA and on Hemodialysis

Study of TA-NIC to Assess the Efficacy and Safety of the Vaccine as an Aid to Smoking Cessation

Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Recombinant Coagulation Factor VIII Fc Fusion Protein (rFVIIIFc) in Previously Treated Pediatric Subjects With Hemophilia A

Trial of Aeroquin Versus Tobramycin Inhalation Solution (TIS) in Cystic Fibrosis (CF) Patients

RhinAer Procedure for Treatment of Chronic Rhinitis Study

Phase 3 Study of LUM-201 in Children With Growth Hormone Deficiency

Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)

Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)

Study of Aripiprazole in the Treatment of Children and Adolescents With Autistic Disorder (AD)

Post Approval Study of the TS Feature With the 530G Pump System Supplemented With Commercial Patient Data

S0101 Gemcitabine and Irinotecan in Treating Patients With Metastatic or Recurrent Cancer of the Esophagus

PF-07304814 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)

Study to Assess the Efficacy and Safety of Simtuzumab (GS-6624) in Adults With Idiopathic Pulmonary Fibrosis (IPF)

GR270773 In The Treatment Of Suspected Or Confirmed Gram-Negative Severe Sepsis In Adults

Chemotherapy and Pelvic Radiation Therapy With or Without Additional Chemotherapy in Treating Patients With High-Risk Early-Stage Cervical Cancer After Radical Hysterectomy

Does Cefoxitin or Piperacillin-Tazobactam Prevent Postoperative Surgical Site Infections After Pancreatoduodenectomy?

Study of Pregabalin Versus Placebo in the Treatment of Nerve Pain Associated With HIV Neuropathy

California Transport Cooling Trial

Comparison of the Human Acellular Vessel (HAV) With ePTFE Grafts as Conduits for Hemodialysis

Efficacy and Safety of Voclosporin to Treat Active Noninfectious Uveitis

ECOSPOR IV: An Open-Label Study Evaluating SER-109 in Recurrent Clostridioides Difficile Infection

Sham-Controlled Rapid-Acting Neuromodulation for Depression

COVID-19 Study Assessing the Efficacy and Safety of Anti-Spike SARS CoV-2 Monoclonal Antibodies for Prevention of SARS CoV-2 Infection Asymptomatic in Healthy Adults and Adolescents Who Are Household Contacts to an Individual With a Positive SARS-CoV-2 RT-PCR Assay